In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy) enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]
Men with metastatic castrate resistant prostate cancer (mCRPC) have become fortunate over the last few years as there we now have a number of new drugs available which can extend our life and can also have some palliative effects. However, as we have more treatments being approved, we find that we are faced with a [...]
Intermittent hormone therapy (IHT) as opposed to continuous hormone therapy (CHT) provides a better quality of life (QoL) for men with locally advanced prostate cancer. However, there is a debate created by a few major research protocols that have been inconclusive as to the difference in achieving the ultimate goal, survival despite prostate cancer. Researchers [...]
Clinical trials for treatment of men with advanced prostate cancer often don’t include men who are considered very elderly (aged over 80 years). So, even if we know that a treatment is tolerable and effective in the average man, we can not assume that it would also be in the very elderly, especially in reference [...]
I have been informed that it is now possible for men in need of the treatment Xofigo to obtain it without having to pay any co-pays. The program that is making this possible is called Xofigo Access Services and is designed to make Xofigo available for men with a commercial medical insurance policy (not medicaid [...]
Traditional hormone therapy usually consists of two types of drugs; GnRH agonists (like Lupron and Zoladex) and antiandrogens (Casodex). Although they both are drugs that manipulate the hormone system their modes of action are different. GnRH agonists block the production of the male hormone testosterone while the antiandrogen drug blocks the ability of the prostate [...]
There is a lot of evidence that pre-treatment rehabilitation (prehabilitation or pre-hab) both speeds up and benefits a patient’s recovery after surgical orthopedic treatment for knee and hip replacement as well as cardiac conditions. Having pre-hab, which is often covered by insurance after orthopedic surgery, is pretty standard. Now, based on an article published in [...]
During last year’s American Society of Clinical Oncologists (ASCO) Annual Meeting, data was released from the STAMPEDE trial which should change clinical practice around the world. The trial results showed that newly diagnosed men with very aggressive prostate cancer that was still hormone therapy naive (no ADT) would have a very significant survival advantage by [...]
Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]
Provenge, despite its demonstrated survival advantage, continues to be knocked as a viable treatment for men with castrate-resistant prostate cancer. What is Provenge? Provenge is immunotherapy for men with metastatic castrate-resistant prostate cancer. In other words, Provenge might help men live longer after their cancer has spread outside of the prostate and are no [...]
